Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial

Targeting gp100 and TRP-2 with a DNA vaccine: incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial

A DNA vaccine, SCIB1, incorporating two CD8 and two CD4 epitopes from TRP-2/gp100 was evaluated in patients with metastatic melanoma. Each patient received SCIB1 via intramuscular injection with electroporation. The trial was designed to find the safest dose of SCIB1 which induced immune/clinical re...

Full description

Bibliographic Details
Main Authors: Patel, Poulam M., Ottensmeier, Christian H., Mulatero, Clive, Lorigan, Paul, Plummer, Ruth, Pandha, Hardev S., Elsheikh, Somaia, Hadjimichael, Efthymios, Villasanti, Naty, Cunnell, Michelle, Metheringham, Rachael L., Brentville, Victoria A., Machado, Lee, Daniels, Ian, Gijon, Mohamed, Hannaman, Drew, Durrant, Lindy
Format: Article
Published: Taylor & Francis 2018
Subjects:
Immunotherapy
vaccine
melanoma
T-cell
Online Access:https://eprints.nottingham.ac.uk/49782/

Similar Items

Similar Items